Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable ...

Primerica’s second quarter was shaped by diverging trends across its core business lines, with management attributing ...

Jefferies analyst Suneet Kamath maintained a Hold rating on Primerica yesterday and set a price target of $283.00. The company’s shares closed yesterday at $258.27. Take advantage of TipRanks Premium ...

Greetings, and welcome to Primerica's Second Quarter 2025 Earnings webcast. [Operator Instructions] Please note that this ...

KBW analyst Ryan Krueger maintained a Hold rating on Primerica today and set a price target of $315.00. The company’s shares closed yesterday at $255.46. Elevate Your Investing ...

Financial services company Primerica (NYSE:PRI) reported Q2 CY2025 results , with sales up 7.1% year on year to $793.3 million. Its non-GAAP profit of $5.46 per share was 4.9% above analysts’ ...

NYSE:PRI 1 Year Share Price vs Fair Value Explore Primerica's Fair Values from the Community and select yours ...